Literature DB >> 287373

Subacute myeloid leukemia: a clinical review.

J R Cohen, W P Creger, P L Greenberg, S L Schrier.   

Abstract

The data on 31 patients who fit into the clinical spectrum of subacute myeloid leukemia have been reviewed. The majority of patients were male with a median age of 61 years. The interval from onset of symptoms to actual diagnosis was extremely variable, with a mean of 16 months and a median of six months. Most patients presented with anemia and thrombocytopenia, although the white blood cell count varied from striking leukopenia to marked leukocytosis. Examination of the bone marrow invariably revealed abnormalities of all cell lines with megaloblastoid erythrogenesis and dysplastic megakaryocytopoiesis. Although the white cell line showed prominence of immature forms, there was more maturation than is seen in acute myeloid leukemia. Survival from diagnosis was variable, from less than one month to greater than 68 months, with a median of only six months. Anemia and hepatosplenomegaly were prognosticators of a poor outlook; patients with hepatosplenomegaly in association with either leukocytosis or thrombocytopenia had a particularly poor outlook, with a median survival of only one and a half months. Approximately half the patients received chemotherapy with no demonstrated effect on survival.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 287373     DOI: 10.1016/0002-9343(79)90451-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  2 in total

1.  A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.

Authors:  D R Gandara; C A Ries; S A Schiff; C B George; J P Lewis; M M Koretz; S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Natural history of smouldering leukaemia.

Authors:  A S Joseph; K I Cinkotai; L Hunt; C G Geary
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.